Nature Reviews Drug Discovery

Epigenetic editing: from concept to clinic

Elizabeth A. Heller, Lacramioara Bintu, Marianne G. Rots Mar 01, 2026 pp. 227-248 10.1038/s41573-025-01323-0

Human organoids as 3D in vitro platforms for drug discovery: opportunities and challenges

Daisong Wang, Remi Villenave, Nadine Stokar-Regenscheit et al. Mar 01, 2026 pp. 204-226 10.1038/s41573-025-01317-y

Innovative antibody therapeutic development in China compared with the USA and Europe

Silvia Crescioli, Janice M. Reichert Mar 01, 2026 pp. 169-170 10.1038/d41573-025-00185-w

Induced proximity-based therapeutic modalities

Elizabeth A. King, Margot Meyers, Daniel K. Nomura Mar 01, 2026 pp. 175-203 10.1038/s41573-025-01316-z

PIP4K2C: an emerging fulcrum for multiple diseases

Luca Pozzetti, Manjari Mishra, Shirit Einav et al. Mar 01, 2026 pp. 166-166 10.1038/d41573-026-00030-8

TIGIT’s immuno-oncology teachings

Asher Mullard Mar 01, 2026 pp. 157-161 10.1038/d41573-026-00031-7

Approvals by the China NMPA in 2025

Ran Jing, Xiecheng Zhi, Liming Shao Mar 01, 2026 pp. 164-165 10.1038/d41573-026-00028-2

2025’s FDA approvals by regulatory designations

Asher Mullard Mar 01, 2026 pp. 163-163 10.1038/d41573-026-00026-4

PD1 blockers work best when used in the morning, suggests cancer chronotherapy trial

Asher Mullard Mar 01, 2026 pp. 162-162 10.1038/d41573-026-00025-5

GSK pays US$2 billion for prophylactic food allergen antibody

Asher Mullard Mar 01, 2026 pp. 162-162 10.1038/d41573-026-00024-6

Antibody–lectin chimeras: new checkpoint inhibitors in the toolbox

M. Teresa Villanueva Mar 01, 2026 pp. 173-173 10.1038/d41573-026-00023-7

Two-step screen for CARD9 inhibitors

Alex Eccleston Mar 01, 2026 pp. 172-172 10.1038/d41573-026-00022-8

Lipid flippase inhibitor tackles drug-resistant fungi

Sarah Crunkhorn Mar 01, 2026 pp. 174-174 10.1038/d41573-026-00018-4

Predicting small-molecule–RNA interactions

Sarah Crunkhorn Mar 01, 2026 pp. 174-174 10.1038/d41573-026-00021-9

Mapping covalent drug targets

Sarah Crunkhorn Mar 01, 2026 pp. 174-174 10.1038/d41573-026-00019-3

Spatiotemporal in vivo protein degradation

Sarah Crunkhorn Mar 01, 2026 pp. 174-174 10.1038/d41573-026-00020-w

Olfactory receptor activation overcomes obesity

Sarah Crunkhorn Mar 01, 2026 pp. 171-171 10.1038/d41573-026-00015-7

The Biomarkers Consortium: 20 years of advancing precision medicine

Amanda Klein, Jeffrey Siegel, Steve Hoffmann et al. Mar 01, 2026 pp. 155-156 10.1038/d41573-025-00187-8

Hunting for biopharma’s innovation sweet spot

Asher Mullard Mar 01, 2026 pp. 167-168 10.1038/d41573-026-00011-x